ANNAPOLIS, Md., Jan. 8 /PRNewswire/ -- PharmAthene, Inc., a leading
biodefense company specializing in the development and commercialization of
medical countermeasures against chemical and biological terrorism,
announced today that it has appointed Christopher C. Camut Vice President
and Chief Financial Officer, effective immediately.
Mr. Camut brings more than fourteen years of experience in healthcare
and technology corporate finance and investment banking. Prior to joining
PharmAthene Mr. Camut served as Chief Financial Officer for RecoverCare
LLC, a specialty medical equipment provider based in Plymouth Meeting,
Pennsylvania. While at RecoverCare, Mr. Camut was responsible for the
overall financial management of the company as well as a member of the
company's mergers and acquisitions team. Prior thereto, Mr. Camut was a
Managing Director for Wachovia Securities' Equity Capital Markets and the
Corporate and Investment Banking Group. Prior to Wachovia, Mr. Camut was a
Principal with both ABS Capital Partners and Alex. Brown & Sons Health Care
Investment Banking. Mr. Camut started his career on Wall Street with
Kidder, Peabody & Company.
David P. Wright, President and Chief Executive Officer, commented, "We
are delighted to welcome Chris as a new member of PharmAthene's senior
management team. His extensive capital markets knowledge and impressive
network of relationships within the healthcare financial community,
combined with an exceptional financial and operational acumen, will be a
significant asset to PharmAthene as we continue to advance our corporate
and financial goals."
Mr. Camut received his MBA from the University of Chicago Graduate
School of Business, Chicago, Illinois, and a BS in Chemical Engineering
from the University of Maryland, College Park, Maryland.
About PharmAthene, Inc.
PharmAthene, a privately-held biotechnology company, is dedicated to
the rapid development of important and novel medical countermeasures to
address biological pathogens and chemicals that may be used as weapons of
bioterror. PharmAthene's lead programs include Valortim(TM), intended for
the prevention and treatment of anthrax, which is being co-developed with
Medarex, Inc., and Protexia(R), intended to prevent and treat nerve agent
toxicity. PharmAthene is located in the Chesapeake Innovation Center in
Annapolis, MD, America's first business accelerator for the homeland and
national security sectors. PharmAthene has been successful in obtaining
U.S. Government and Venture Capital funding to finance the development of
its portfolio products. For more information on PharmAthene, please visit
http://www.PharmAthene.com.
SOURCE PharmAthene, Inc.
 back to top
Related links:
http://www.pharmathene.com
CONTACT:
Stacey Jurchison, Director, Corporate
Communications of PharmAthene, Inc., +1-410-571-8925, Cell:
+1-410-474-8200, JurchisonS@PharmAthene.com
|
